eFFECTOR Therapeutics, Inc. financial data

Symbol
EFTR, EFTRW on OTC
Industry
Pharmaceutical Preparations
Location
142 North Cedros Avenue, Suite B, Solana Beach, CA
State of incorporation
DE
Fiscal year end
December 31
Former names
Locust Walk Acquisition Corp. (to 8/25/2021)
Latest financial report
10-Q - Q1 2024 - May 9, 2024

Key Ratios

Label TTM Value / Value Unit Change %
Current Ratio 92.5 % -26.8%
Debt-to-equity -1.59K % -577%
Return On Equity 2.18K %
Return On Assets -146 % -34.1%

Shares

Label TTM Value / Value Unit Change %
Entity Common Stock, Shares Outstanding 4.7M shares -88.9%
Common Stock, Shares, Outstanding 3.9M shares -90.7%
Common Stock, Value, Issued 0 USD -100%
Weighted Average Number of Shares Outstanding, Basic 4.08M shares +143%
Weighted Average Number of Shares Outstanding, Diluted 4.08M shares +143%

Income Statement

Label TTM Value / Value Unit Change %
Revenue from Contract with Customer, Excluding Assessed Tax 0 USD -100%
Research and Development Expense 21.6M USD -19.4%
General and Administrative Expense 11.1M USD -8.62%
Operating Income (Loss) -32.7M USD +7.59%
Nonoperating Income (Expense) -1.93M USD -440%
Net Income (Loss) Attributable to Parent -34.6M USD +3.13%
Earnings Per Share, Basic -12.6 USD/shares +36.5%
Earnings Per Share, Diluted -12.6 USD/shares +36.5%

Balance Sheet

Label TTM Value / Value Unit Change %
Cash and Cash Equivalents, at Carrying Value 15.5M USD +50.4%
Cash, Cash Equivalents, and Short-term Investments 25.4M USD +33.7%
Assets, Current 26.3M USD +25.6%
Property, Plant and Equipment, Net 190K USD -11.2%
Operating Lease, Right-of-Use Asset 225K USD +132%
Assets 27.1M USD +23.7%
Accounts Payable, Current 1.71M USD -54.9%
Employee-related Liabilities, Current 978K USD +43.8%
Accrued Liabilities, Current 3.79M USD +48.2%
Liabilities, Current 25.6M USD -4.06%
Operating Lease, Liability, Noncurrent 179K USD +316%
Liabilities 26.3M USD -1.63%
Accumulated Other Comprehensive Income (Loss), Net of Tax 0 USD -100%
Retained Earnings (Accumulated Deficit) -188M USD -22.5%
Stockholders' Equity Attributable to Parent 827K USD
Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest 827K USD
Liabilities and Equity 27.1M USD +23.7%

Popular Metrics

Label TTM Value / Value Unit Change %
Net Cash Provided by (Used in) Operating Activities -7.28M USD +4.7%
Net Cash Provided by (Used in) Financing Activities 14.2M USD +6613%
Net Cash Provided by (Used in) Investing Activities -6.32M USD -170%
Common Stock, Shares Authorized 40M shares -96%
Common Stock, Shares, Issued 3.91M shares -90.8%
Common Stock, Par or Stated Value Per Share 0 USD/shares 0%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect 633K USD -60.5%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents 15.5M USD +50.4%
Interest Paid, Excluding Capitalized Interest, Operating Activities 655K USD +11.2%
Deferred Tax Assets, Valuation Allowance 64.7M USD +14.1%
Deferred Tax Assets, Gross 64.7M USD +14.1%
Operating Lease, Liability 232K USD +113%
Comprehensive Income (Loss), Net of Tax, Attributable to Parent -34.6M USD +2.98%
Property, Plant and Equipment, Gross 542K USD +18.3%
Operating Lease, Liability, Current 53K USD -19.7%
Operating Lease, Weighted Average Discount Rate, Percent 0.12 pure +50%
Lessee, Operating Lease, Liability, to be Paid, Year Three 62K USD 0%
Deferred Tax Assets, Operating Loss Carryforwards 46.4M USD +9.76%
Preferred Stock, Shares Issued 0 shares
Preferred Stock, Shares Authorized 100M shares 0%
Unrecognized Tax Benefits 9.82M USD +10.8%
Operating Lease, Payments 105K USD +9.38%
Additional Paid in Capital 189M USD +27.1%
Preferred Stock, Shares Outstanding 0 shares
Depreciation, Depletion and Amortization 28K USD 0%
Deferred Tax Assets, Net of Valuation Allowance 64.7M USD +14.1%
Share-based Payment Arrangement, Expense 4.4M USD -18.5%
Interest Expense 2.98M USD +21%
Preferred Stock, Par or Stated Value Per Share 0 USD/shares 0%